Minneapolis, MN, United States of America

Michael Travanty

This inventor holds 23 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Injection Device Technology. Top assignees: Antares Pharma, Inc., Halozyme, Inc., Alexandria Research Technologies, LLC. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Travanty. Retrieved from https://idiyas.com/inventor/michael-travanty

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 87.0

 

 

Average Co-Inventor Count = 2.2

ph-index = 7

Forward Citations = 117(Granted Patents)


Location History:

  • Wayzata, MN (US) (2021)
  • S. Minneapolis, MN (US) (2016 - 2022)
  • Minneapolis, MN (US) (2011 - 2023)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Needle Assisted Injection
Injection Device
Syringe Shock Absorber
Variable Dosing
Jet Injection
Surface Sculpting
Medical Devices
Trigger Force
23 patents (USPTO):Explore Patents

Title: The Innovative Journey of Michael Travanty

Introduction

Michael Travanty, an accomplished inventor based in Minneapolis, MN, has made significant contributions to the field of medical device technology. With a total of 15 patents to his name, Travanty is recognized for his innovative solutions that enhance the efficiency of injection devices. His work exemplifies the spirit of modern invention focused on improving healthcare outcomes.

Latest Patents

Among his latest innovations are two notable patents for needle-assisted injection devices that have reduced trigger force. The first patent describes an injector with a trigger mechanism that includes a trigger member positioned around an axis, which contains an aperture and a protrusion. This design is complemented by a ram assembly that pressurizes a medicament container, facilitating the expulsion of medication. Additionally, an energy source powers the ram, while a firing-initiation member allows users to transition the trigger member from a pre-firing condition to a firing condition, ultimately releasing the trigger engagement member to fire the ram.

The second patent also details an injector that incorporates a floating trigger member, which interacts with a ram assembly designed to pressurize medication while ensuring effective energy use for expelling the medicament. This design focuses on user operability, allowing a smooth transition between firing conditions, signifying a notable advancement in injection technology.

Career Highlights

Michael Travanty has had a notable career marked by his work with reputable companies such as Antares Pharma, Inc. and Alexandria Research Technologies, LLC. His roles within these organizations have enabled him to push the boundaries of medical device innovation, focusing on user-friendly designs and enhanced effectiveness in drug administration.

Collaborations

Throughout his innovative journey, Travanty has collaborated with skilled professionals, including coworkers Patrick Madsen and Thomas Edward KraMer. These partnerships have contributed to the successful development of cutting-edge injection devices, showcasing the importance of collaboration in the realms of invention and innovation.

Conclusion

Michael Travanty's impressive portfolio of 15 patents and his ongoing contributions to the field of medical technology reflect his dedication to innovation. His latest inventions in needle-assisted injection devices illustrate his commitment to improving healthcare delivery systems. As he continues to expand his expertise, Travanty stands as a key figure in the landscape of contemporary inventors, inspiring future advancements and innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…